Insight Molecular Diagnostics Inc.
HealthcareNASDAQ:IMDX · NASDAQ Capital Market
+$0.18 today
Vol 0.39M · Avg 0.37M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
159.6%
avg -93.0%
ROIC
-197.4%
avg -121.5%
ROA
-195.0%
avg -102.6%
Analysis
ROE is currently the strongest return metric at 159.6% versus its period average of -93.0%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joshua Riggs | President, Chief Executive Officer & Director | $662,787.00 | — | 43 | $141,509.00 | 0.53% |
Ekkehard Schutz | Chief Science Officer | $552,014.00 | — | — | — | — |
Andrea Susan James | Chief Financial Officer | $536,578.00 | — | 44 | $206,060.00 | 0.77% |
James Liu | Vice President of Accounting, Treasurer, Controller & Principal Accounting Officer | $303,253.00 | — | 30 | $206,060.00 | 0.77% |
Michael D. West | Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. | — | — | 73 | $60,000.00 | 0.22% |
Paul R. Billings FACP | Consulting Chief Medical Officer | — | — | 74 | — | — |
Peter Hong | Vice President, General Counsel & Secretary | — | — | — | $0.00 | <0.01% |
Steven Tahmooressi | Vice President of Marketing | — | — | — | — | — |
Yuh-Min Chiang | Chief Technology Officer | — | — | — | — | — |
Gabrielle Woody | Sr. Executive Assistant | — | — | — | — | — |
Sandra O'Donald | Senior Vice President of Business Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
14
$5.69M
Sells
0
$0.00
Net Sentiment
+$5.69M
Net buying
Most Active
BROADWOOD PARTNERS, L.P.
14 transactions
1–10 of 14
Analysis
Insiders reported 14 buys worth $5.69M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $5.69M. BROADWOOD PARTNERS, L.P. was the most active insider with 14 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Cybin Inc.
CYBN
$413.02M
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$352.45M
C4 Therapeutics, Inc.
NASDAQ:CCCC
$323.03M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$278.27M
OmniAb, Inc.
NASDAQ:OABI
$270.34M
Codexis, Inc.
NASDAQ:CDXS
$218.15M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$109.08M
Invivyd, Inc.
NASDAQ:IVVD
$102.20M
PepGen Inc.
NASDAQ:PEPG
$101.68M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$64.96M
Who manages IMDX?
Insight Molecular Diagnostics Inc. (IMDX) lists 11 active executives. The top listed executive is James Liu, Vice President of Accounting, Treasurer, Controller & Principal Accounting Officer.
Are IMDX insiders buying or selling?
Recent insider activity shows net buying of $79.37M.
Explore More
Continue the stock analysis
Jump to another research area for this company.